Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Using Autologous T Cell Engineered With Chimeric Antigen Receptor Targeting to CD19（Cluster of Differentiation Antigen 19) in Treating Patients With Recurrent /Refractory B Cell Leukemia

NCT02644655 is registered in ClinicalTrials.gov with Second Military Medical University as lead sponsor.

NCT NCT02644655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02644655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Using Autologous T Cell Engineered With Chimeric Antigen Receptor Targeting to CD19（Cluster of Differentiation Antigen 19) in Treating Patients With Recurrent /Refractory B Cell Leukemia
Lead sponsor
Second Military Medical University
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2015
Completion date
September 30, 2017
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell tumor, refractory b-cell tumor